| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
|
J Clin Oncol
|
2002
|
13.81
|
|
2
|
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
|
Breast Cancer Res Treat
|
2011
|
2.73
|
|
3
|
Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment.
|
J Am Coll Surg
|
2009
|
2.18
|
|
4
|
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
|
Clin Cancer Res
|
2011
|
1.78
|
|
5
|
Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management.
|
J Clin Oncol
|
2004
|
1.70
|
|
6
|
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
|
Proc Natl Acad Sci U S A
|
2006
|
1.61
|
|
7
|
Qualitative research contribution to a randomized clinical trial.
|
Res Nurs Health
|
2005
|
1.54
|
|
8
|
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study.
|
Cancer
|
2004
|
1.50
|
|
9
|
Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications.
|
Oncologist
|
2004
|
1.37
|
|
10
|
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers.
|
Clin Breast Cancer
|
2005
|
1.25
|
|
11
|
Putting cancer pain management regimens into practice at home.
|
J Pain Symptom Manage
|
2002
|
1.22
|
|
12
|
Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.
|
Breast Cancer Res
|
2011
|
1.22
|
|
13
|
Integrative Oncology Practice Guidelines.
|
J Soc Integr Oncol
|
2007
|
1.21
|
|
14
|
Traditional Chinese medicine in the treatment of breast cancer.
|
Semin Oncol
|
2002
|
1.19
|
|
15
|
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
|
Breast Cancer Res Treat
|
2014
|
1.10
|
|
16
|
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.
|
Pain
|
2004
|
1.08
|
|
17
|
The PRO-SELF pain control program improves patients' knowledge of cancer pain management.
|
Oncol Nurs Forum
|
2004
|
1.07
|
|
18
|
IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation.
|
J Biol Chem
|
2005
|
1.04
|
|
19
|
A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.03
|
|
20
|
Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study.
|
J Magn Reson Imaging
|
2012
|
1.02
|
|
21
|
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.
|
Breast Cancer Res Treat
|
2006
|
1.02
|
|
22
|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
|
J Clin Oncol
|
2003
|
1.00
|
|
23
|
No evidence for sex differences in the severity and treatment of cancer pain.
|
J Pain Symptom Manage
|
2004
|
0.98
|
|
24
|
The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management.
|
Pain
|
2007
|
0.98
|
|
25
|
The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management.
|
Oncol Nurs Forum
|
2003
|
0.97
|
|
26
|
Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain.
|
J Pain Symptom Manage
|
2007
|
0.97
|
|
27
|
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
|
Clin Cancer Res
|
2011
|
0.95
|
|
28
|
Pain management autobiographies and reluctance to use opioids for cancer pain management.
|
Cancer Nurs
|
2002
|
0.94
|
|
29
|
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
|
J Clin Oncol
|
2012
|
0.93
|
|
30
|
Managing metastatic bone pain: the role of bisphosphonates.
|
J Pain Symptom Manage
|
2007
|
0.92
|
|
31
|
Aromatase inhibitors: rationale and use in breast cancer.
|
Annu Rev Med
|
2005
|
0.91
|
|
32
|
Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
|
BMC Med
|
2014
|
0.89
|
|
33
|
Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain.
|
J Pain
|
2011
|
0.88
|
|
34
|
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
|
Breast Cancer Res Treat
|
2012
|
0.88
|
|
35
|
Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer.
|
J Med Internet Res
|
2012
|
0.84
|
|
36
|
The usefulness of a daily pain management diary for outpatients with cancer-related pain.
|
Oncol Nurs Forum
|
2002
|
0.84
|
|
37
|
Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience.
|
Clin Drug Investig
|
2006
|
0.82
|
|
38
|
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
|
Curr Opin Obstet Gynecol
|
2014
|
0.80
|
|
39
|
Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods.
|
BMC Cancer
|
2014
|
0.80
|
|
40
|
Developing safety criteria for introducing new agents into neoadjuvant trials.
|
Clin Cancer Res
|
2013
|
0.80
|
|
41
|
Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner.
|
PLoS One
|
2013
|
0.80
|
|
42
|
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
|
Acta Pharmacol Sin
|
2006
|
0.79
|
|
43
|
Survival impact of integrative cancer care in advanced metastatic breast cancer.
|
Breast J
|
2009
|
0.79
|
|
44
|
Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control.
|
J Pain
|
2002
|
0.78
|
|
45
|
Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain during participation in a psychoeducational intervention study to improve pain management.
|
J Pain
|
2011
|
0.78
|
|
46
|
Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable.
|
Clin Breast Cancer
|
2008
|
0.78
|
|
47
|
Radiologist's role in breast cancer staging: providing key information for clinicians.
|
Radiographics
|
2014
|
0.78
|
|
48
|
The challenges of randomized trials in integrative cancer care.
|
Integr Cancer Ther
|
2004
|
0.77
|
|
49
|
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
|
Clin Breast Cancer
|
2010
|
0.77
|
|
50
|
Are we hitting the right combination for hormonally sensitive breast cancer?
|
J Clin Oncol
|
2009
|
0.77
|
|
51
|
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.77
|
|
52
|
Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2015
|
0.77
|
|
53
|
Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.
|
Breast J
|
2015
|
0.76
|
|
54
|
Breast cancer quality care: what is at stake?
|
Breast J
|
2012
|
0.75
|
|
55
|
New treatment paradigms for optimizing survival in advanced and metastatic breast cancer.
|
Clin Adv Hematol Oncol
|
2012
|
0.75
|
|
56
|
Using neoadjuvant therapy for breast cancer in clinical practice: when and how?
|
Breast Cancer Res Treat
|
2012
|
0.75
|
|
57
|
Biologically targeted therapy: as good as advertized?
|
Clin Breast Cancer
|
2003
|
0.75
|
|
58
|
Erratum. Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer.
|
J Natl Cancer Inst Monogr
|
2015
|
0.75
|
|
59
|
Anthropometric Measurements and Cardiorespiratory Fitness in Breast Cancer Survivors: 2959 Board #24 June 3, 2: 00 PM - 3: 30 PM.
|
Med Sci Sports Exerc
|
2016
|
0.75
|
|
60
|
Point-counterpoint: soy intake for breast cancer patients.
|
Integr Cancer Ther
|
2002
|
0.75
|
|
61
|
Integrative tumor board: metastatic breast cancer.
|
Integr Cancer Ther
|
2006
|
0.75
|
|
62
|
Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007.
|
Support Cancer Ther
|
2007
|
0.75
|
|
63
|
Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance.
|
Biomarkers
|
2015
|
0.75
|